Columnist Joe MacDonald describes his early adjustments to cope with the reality of his oldest son's hemophilia.

Certain immune markers in the blood may help predict ITI response among hemophilia A patients given immune tolerance ...

While packing for a move, the youngest son of columnist Cazandra Campos-MacDonald experiences a regular guest: joint pain.

Preventive treatment with Pfizer's Hympavzi can reduce bleeding rates in hemophilia A or B patients with inhibitors, new ...

Like many with hemophilia, columnist G Shellye Horowitz requires IV infusions of her medication — but the scars can raise some eyebrows.

Directly switching from Hemlibra to Mim8 was well tolerated in people with hemophilia A, with or without inhibitors, a study ...

A study reveals that the majority of Chinese patients with hemophilia A depend on on-demand therapy, resulting in limited ...

Columnist G Shellye Horowitz struggles to find care for her gastrointestinal issues due to the shortage of medical providers ...

The results of gene therapy for hemophilia B contrast with those of factor replacement therapies, where lifelong infusions ...

No description.G Shellye Horowitz, MA, PPS, has strong ties to the bleeding disorders community with six traceable generations of hemophilia A in her family. She also has hemophilia A. Her advocacy ...

No description.There is no cure for hemophilia, but there are treatments available that can help manage the disease and maintain quality of life. In addition to existing approved treatments, several ...

Hemophilia type A, sometimes called classic hemophilia, is the most common. It’s caused by a deficiency in FVIII. Hemophilia type B, also known as Christmas Disease, is the second-most common type. It ...